Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $243,656.89 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,013 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $240.53, for a total value of $243,656.89. Following the completion of the sale, the insider directly owned 143,686 shares of the company’s stock, valued at approximately $34,560,793.58. This represents a 0.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The shares were sold at an average price of $237.66, for a total value of $285,192.00.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total transaction of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00.

Natera Trading Down 0.1%

NTRA opened at $231.14 on Friday. The stock has a fifty day moving average price of $235.91 and a 200 day moving average price of $194.11. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The stock has a market cap of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period last year, the business earned ($0.26) earnings per share. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several analyst reports. Wells Fargo & Company lifted their price objective on shares of Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. Evercore ISI boosted their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $249.20.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NTRA. Horizon Investments LLC acquired a new stake in Natera during the third quarter worth about $32,000. Hilltop National Bank bought a new stake in shares of Natera in the 2nd quarter worth approximately $33,000. Sound Income Strategies LLC grew its holdings in shares of Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in shares of Natera during the fourth quarter valued at approximately $41,000. Finally, Quent Capital LLC acquired a new position in shares of Natera in the third quarter valued at $46,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.